Companies: 10,795·Total market cap: $144.5T
ADC Therapeutics S.A.

ADC Therapeutics S.A.

ADCTNYSEHealthcare● Active
$0.95
$-0.08(-7.40%)
Market Cap$121314776
P/E Ratio
52W High$4.98
52W Low$0.7796
Overview
Foreign Private Issuer · Files 20-F / 6-K

ADC Therapeutics S.A. (ADCT) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001771910 · ADCT · NYSE · as of Jun 8, 2026

Filing snapshot

423
Total Filings
4
Latest Form
2026-06-03
Most Recent
2020
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001771910 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-10
Fiscal Year End
Mar 10, 2026
Accession No.
0001628280-26-016491
Primary Document
adc-20251231.htm
Source: data.sec.gov · CIK 0001771910 · Accession 0001628280-26-016491

Latest Key Filings

6-KQuarterly Report
FORM 6-K
2023-12-19
8-KCurrent Report
FORM 8-K
2026-06-03Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
FORM 8-K
2026-06-03
View
8-KCurrent Report
FORM 8-K
2026-06-02
View
10-QQuarterly Report
10-Q
2026-05-04
View
8-KCurrent Report
8-K
2026-05-04
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-24
View
DEFA14AProxy Statement (Additional)
FORM DEFA14A
2026-04-20
View
DEF 14AProxy Statement
DEF 14A
2026-04-20
View
424B3424B3
FORM 424B3
2026-04-15
View
PRE 14APRE 14A
PRE 14A
2026-04-10
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-06
View
EFFECTEFFECT
EFFECT
2026-03-16
View
424B3424B3
FORM 424B3
2026-03-16
View
CORRESPCORRESP
CORRESP
2026-03-12
View
UPLOADUPLOAD
UPLOAD
2026-03-12
View
S-3Shelf Registration
FORM S-3
2026-03-10
View
Showing 1–15 of 352 filingsForm 4 / 144 hidden· 423 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001771910  |  Exchange: NYSE · Healthcare

ADC Therapeutics S.A. (NYSE: ADCT) has submitted 423 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001771910, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is ADC Therapeutics S.A.'s most comprehensive regulatory disclosure. The most recent ADC Therapeutics S.A. 10-K was filed on 2026-03-10 for fiscal year ending 2026. Historical ADCT 10-K annual reports are available from 2019 through 2026.

Investors researching ADC Therapeutics S.A. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

ADCT SEC Filings · 8 questions

ADC Therapeutics S.A. (ADCT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 423 filings and access original documents at no cost. ADC Therapeutics S.A.'s CIK is 0001771910.

ADCT SEC filingsADC Therapeutics S.A. SEC documentsfind ADCT 10-K